Abstract:

ABSTRACT  Objective:To evaluate the efficacy and safety of rabbit anti-human T lymphocyte immune globulin (ATG-F )and Basiliximab for individualized immune induction therapy in kidney transplantation, and to further discuss the individualized treatment regime in the immune induction of kidney transplantation.  Methodology: Three hundred eighty one cases with kidney transplant, including rabbit anti-human T lymphocyte immune globulin (ATG-F)-Induced 179 cases, Basiliximab-Induced 124 cases and 78 cases without immune induction therapy as the control group were retrospective analyzed. All recipients after kidney transplantation were accepted conventional immunosuppressive regimens for anti-rejection therapy. General situation of different groups in patients with preoperative and postoperative graft function recovery, the survival rate of patient and kidney within one year and early complications were analyzed and compared.  Results: There was no significant difference in the acute rejection incidence, early graft function recovery, the survival rate of patient and kidney within one year between ATG-F group and Basiliximab group（P＞0.05）, but which were better than that of control group（P＜0.05. The incidence of infection and associated-complications in ATG-F group and Basiliximab group were a little more than that of control group, but no significant difference was found in three groups（P＞0.05）. Conclusion: The clinical application of antibody induction therapy was safe and effective for recipients after kidney transplantation, but should strictly observe the principle of selection of indications and contraindications, taking individual induction therapy, preventing associated complications, which may effectively reduce the incidence of rejection and enhance the survival rate of patients and kidneys.

Key words: Key words , Kidney transplantation , antibody-based biologics , immune induction